Clear Search

Showing 17 results for “Efficacy” published 2022.

January 2023
December 2022

Low-dose Interleukin-2 Therapy in Active Systemic Lupus Erythematosus (LUPIL-2): A Multicentre, Double-blind, Randomised and Placebo-controlled Phase II Trial

Ann Rheum Dis. 2022;81:1685–1694

Phase II proof-of-concept trial confirms that low-dose IL-2 therapy can safely and selectively expand the Treg population, and is capable of reducing disease activity in patients with SLE.

more…

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Arthritis Rheumatol. 2022. Epub ahead of print doi: 10.1002/art.42392

Long-term extension study shows an acceptable long-term safety profile of anifrolumab in SLE, in addition to sustained improvements in disease activity and reduction in glucocorticoid use.

more…

November 2022

Safety and Efficacy of Belimumab in Patients with Lupus Nephritis

Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322

This 28-week, open-label extension of BLISS-LN found no new safety signals and maintained efficacy with belimumab, in patients with lupus nephritis.

more…

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus

N Engl J Med. 2022;387(10):894–904 doi: 10.1056/NEJMoa2118025

Phase 2 study, in patients with systemic lupus erythematosus, shows that litifilimab is associated with a greater reduction from baseline in the number of swollen and tender joints than placebo, over a period of 24 weeks.

more…

September 2022

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

N Engl J Med. 2022;387(4):321–331 doi: 10.1056/NEJMoa2118024

Phase II study, in patients with active cutaneous lupus erythematosus, shows that litifilimab improved scores on a measure of skin disease activity, over 16 weeks, compared to placebo.

more…

Effect and safety profile of belimumab and tacrolimus combination therapy in thirty‑three patients with systemic lupus erythematosus

Clin Rheumatol. 2022. Epub ahead of print doi: 10.1007/s10067-022-06325-6

A single-centre analysis of patients with SLE administered tacrolimus and belimumab shows this combination therapy to be well-tolerated, with a good efficacy profile and glucocorticoid-reducing effect.

more…

July 2022

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

van Vollenhoven RF, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/ard-2022-222858.

Phase 3 study evaluating the efficacy and safety of ustekinumab in patients with active SLE, despite receiving standard-of-care, does not achieve primary and key secondary endpoints.

more…

June 2022

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685

Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.

more…